X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

THERAPIE

期刊標題檢索 THERAPIE 最新評論: Yes (2021-12-30)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[THERAPIE]您好,您是該頁面的第 13730 位訪客。

期刊簡介
期刊名稱THERAPIE THERAPIE
LetPub Score
5.0
50 ratings
Rate

Reputation
6.0

Influence
3.7

Speed
7.0

期刊簡稱THERAPIE
ISSN0040-5957
E-ISSN1958-5578
h-index33
CiteScore
CiteScoreSJRSNIPCiteScore Rank
3.500.4560.733
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Pharmacology (medical)
Q3147 / 272

自引率 (2023-2024)27.30%自引率趨勢
掲載範囲
Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject.
The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
官方網站http://www.therapielv.com/
在線稿件提交
開放訪問No
出版商Elsevier Masson SAS
主題領域医学
出版國/地區FRANCE
發行頻率隔月刊行
創刊年1946
每年文章數73每年文章數趨勢
黃金OA百分比44.50%
Web of Science 四分位
2023-2024
WOS Quartile: Q3

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ3204/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0040-5957%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Easy
參考鏈接
相關期刊 【THERAPIE】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    PHARMACOLOGICAL REVIEWSH-index: 210

    CiteScore: 34.70
    DRUG RESISTANCE UPDATESH-index: 100

    CiteScore: 26.20
    ADVANCED DRUG DELIVERY REVIEWSH-index: 278

    CiteScore: 28.10
    TRENDS IN PHARMACOLOGICAL SCIENCESH-index: 201

    CiteScore: 23.90
    PHARMACOLOGY & THERAPEUTICSH-index: 180

    CiteScore: 23.00
    MEDICINAL RESEARCH REVIEWSH-index: 119

    CiteScore: 29.30
    PHARMACOLOGICAL RESEARCHH-index: 118

    CiteScore: 18.70
    ARCHIVES OF PHARMACAL RESEARCHH-index: 75

    CiteScore: 13.40
    BIOMEDICINE & PHARMACOTHERAPYH-index: 78

    CiteScore: 11.90
    BRITISH JOURNAL OF PHARMACOLOGYH-index: 190

    CiteScore: 15.40
    學科內最受檢索的期刊 頁面查看次數
    BIOMEDICINE & PHARMACOTHERAPY498691
    PHYTOMEDICINE343949
    LIFE SCIENCES291262
    PHARMACOLOGICAL RESEARCH244141
    International Journal of Pharmaceutics242797
    European Journal of Pharmacology204594
    BIOCHEMICAL PHARMACOLOGY203097
    JOURNAL OF NATURAL PRODUCTS196886
    BRITISH JOURNAL OF PHARMACOLOGY165477
    MOLECULAR PHARMACEUTICS162994
  •  

    THERAPIE THERAPIE
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [THERAPIE] 的評論撰寫評論
作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 17:17:37 評論於
Yes
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 15:19:40 評論於
The corresponding author of an SCI journal article does not necessarily have to be only one person, and there is no fixed standard for how many there can be. This is because different SCI journals have different policies regarding the number of corresponding authors. For SCI journals that only accept one corresponding author, if the paper has multiple corresponding authors, the first corresponding author will be automatically selected. For SCI journals that accept two corresponding authors, two corresponding authors can be listed. The same applies to other requirements, so the number of corresponding authors listed by the authors must comply with the regulations of the target SCI journal. The first author of an SCI paper is the person who has made the greatest contributions to the experiments and writing of the article, and is the person who is listed first in the authors section. However, in collaborations involving multiple authors, it is common to have multiple first authors. There is no clear rule regarding the number of co-first authors, as it depends greatly on the workload, length of the paper, requirements of the publishing journal, and recognition from institutions. Generally, having 2-4 first authors for an SCI paper is most common
(0) 讚! | 维尔娜菲茨杰拉德

作者: Oswald Edie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 15:14:58 評論於
How many corresponding authors/first authors can a journal have?
(0) 讚! | Oswald Edie

作者: Oswald Edie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 13:31:21 評論於
Will all authors receive an email after the article is accepted?
(0) 讚! | Oswald Edie

作者: Alger Zimmerman


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2018-07-10 16:50:18 評論於
Review speed: 12.0 | Submission hit rate: 50.0
Experience sharing: with editor: 1 month | First review: 3 months | Revision: 
With editor again: 1 month | Second review: 3 months | Acceptance
It took about 8 months to receive the acceptance letter. If you are in a hurry to publish, don't submit while in school
(0) 讚! | Alger Zimmerman

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-14 18:34:09 評論於
Anyway, with this bearish market sentiment, there is unlikely to be any changes. As long as it doesn't drop, that's fortunate enough
(0) 讚! | 凌霄高洁

作者: 努力啊大胜洋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-06-13 18:39:43 評論於
Review speed: 1.0 | Submission success rate: 5.0
Experience sharing: Major revisions were still rejected
(0) 讚! | 努力啊大胜洋

作者: 匿名


領域:
審稿時間: 0.0 month(s)
結果:


撰寫評論

2013-04-09 14:50:00 評論於
Journal Homepage URL: http://www.pharmacol-fr.org/
(0) 讚! | 匿名

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [THERAPIE] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*